Zenagamtide (formerly Amycretin): trials, results, and current status.
Also searched as amycretin · NNC0487-0111 · AMAZE 7
Zenagamtide, formerly called amycretin, is Novo Nordisk’s investigational single-molecule GLP-1 and amylin receptor agonist. Both a once-daily tablet and a once-weekly injection are in development, so calling it only “the pill” misses half the program.
Is Amycretin now Zenagamtide, and is it a pill?
Yes, Zenagamtide is the current name for the molecule formerly called Amycretin. A once-daily oral tablet and a once-weekly injection are both in development, so it is not only a pill. Both formulations remain investigational, and the small 12-week oral Phase 1 result is not an approved product claim.
Compare Amycretin / Zenagamtide with Retatrutide, without losing the country context.
Put evidence status, ClinicalTrials.gov coverage, official United States records, and qualified US research prices in one view. Blank fields stay blank when the underlying dataset does not support a number.
Investigational clinical program
Official product and seller records attached
Investigational clinical program
What can you conclude about Zenagamtide today?
These are dated program facts, not a cross-trial ranking, approval forecast, personal treatment recommendation, or proof that a same-name online product is the sponsor's medicine.
Novo Nordisk now uses zenagamtide for the asset formerly called amycretin.
Exploratory mean weight change in a small early cohort of 16 participants, versus 1.1% with placebo.
Once-daily oral and once-weekly subcutaneous programs are being developed separately.
A not-yet-recruiting trial plans to compare weekly zenagamtide with weekly semaglutide in 650 adults with obesity.
Know which molecule the result belongs to.
- Sponsor
- Novo Nordisk
- Mechanism
- GLP-1 + amylin receptor agonist
- Route being studied
- Once-daily oral or once-weekly subcutaneous
- Current stage
- Phase 3 development underway
- Featured trial anchors
- NCT06049329 · NCT07503210 · NCT07668414
- Evidence checked
- July 20, 2026
Zenagamtide weight-loss results, with the trial attached.
This visual shows one selected result, not every dose or endpoint in the program. The percentage remains attached to its duration, population, comparator, analysis method, and source.
Evidence checked July 21, 2026Zenagamtide reported 13.1% mean reduction at 12 weeks under the sponsor-reported exploratory phase 1 mean. The comparator recorded 1.1% mean reduction.
Bar lengths share a 0 to 30% visual scale. They describe this selected record and do not make separate trials head-to-head.
- Population
- Adults with obesity or overweight
- Participants
- 16 Active oral cohort only
- Dose
- Oral dose reported in the 12-week cohort
- Primary analysis
- Sponsor-reported exploratory Phase 1 mean
- Regulatory status
- Investigational; not FDA approved
Zenagamtide clinical trials by status, phase, and location.
The current exact-intervention snapshot matches 24 unique NCT records. This chart describes registry coverage and current study fields. It does not compare efficacy, safety, approval probability, eligibility, or treatment access.
Snapshot 2026-07-24Counts use individual locations currently marked Recruiting, not every facility listed on an overall-recruiting study. Repeated centers across studies remain repeated site observations.
What comes after Retatrutide?
Compare Zenagamtide/Amycretin, MariTide, CagriSema, standalone cagrilintide, and survodutide by route, evidence maturity, trial result, and approval status without ranking unrelated studies as one race.
Open the upcoming weight-loss drugs guide →Amycretin / Zenagamtide across 42 countries.
This profile establishes the program identity and its cited clinical or regulatory record. It does not turn a same-name seller listing into the sponsor’s asset or prove authorization, availability, or lawful supply in another destination.
Compare Amycretin / Zenagamtide by country →Compare Amycretin / Zenagamtide by US state →Browse the global peptide country dataset →Is Zenagamtide approved or available in your country?
Start with the United States FDA record, then check the destination that matters to you. Each country page separates drug identity, authorization, product records, seller claims, and supply rules. Directory checked July 20, 2026.
What the record shows - and what it doesn’t.
Trial percentages are kept beside the design details that make them interpretable. Unknowns stay visible instead of being filled with launch speculation.
The 13.1% result was an early signal
Novo Nordisk’s 2024 investor material reported 13.1% mean weight loss after 12 weeks with oral amycretin versus 1.1% with placebo. The active cohort included 16 participants, so the result is useful for explaining why development continued, not for declaring a market winner.
Later Phase 2 data broadened the picture
In 262 adults with type 2 diabetes, Novo Nordisk reported 14.6% observed mean weight reduction with weekly subcutaneous zenagamtide 40 mg at 36 weeks versus 2.1% with pooled placebo. Its dose-response model estimated 14.5%. The dose-finding trial was not a head-to-head comparison against retatrutide or an approved obesity medicine.
AMAZE 7 creates a direct semaglutide question, not an answer
The Phase 3 AMAZE 7 record plans to randomize 650 adults with obesity to weekly zenagamtide or weekly semaglutide, with body-weight change measured through week 84. The record was not yet recruiting when posted on June 25, 2026 and estimates an October 2028 primary completion. A comparative design does not produce a result before the trial is conducted and reported.
“Strongest pill” is not established
The early oral result came from a small Phase 1 cohort and was not a direct comparison with retatrutide, CagriSema, or approved medicines. Cross-trial speed and percentage comparisons are unreliable.
No approved dose or launch date
The oral and injectable formulations remain investigational. A commercial formulation, final dose, FDA decision, price, and insurance coverage are not established.
Tolerability needs Phase 3 context
Novo Nordisk says the safety profile was consistent with incretin and amylin-based therapies, with gastrointestinal events most common. Larger and longer trials are needed to characterize benefits and harms more completely.
The questions behind the search.
Concise answers based on the dated sponsor and trial records below. This is educational reporting, not medical advice.
Are zenagamtide and amycretin the same drug?
Yes. Zenagamtide is the current name for the Novo Nordisk molecule previously called amycretin, also identified in early records as NNC0487-0111. It is a single, long-acting peptide designed to activate both GLP-1 and amylin receptors. Older trial results and references still use amycretin, while newer sponsor announcements and Phase 3 records increasingly use zenagamtide. Following both names prevents older evidence and newer development updates from becoming disconnected.
Is zenagamtide an oral weight-loss pill?
An oral tablet is one part of the program, but zenagamtide is not only a pill. Novo Nordisk is developing once-daily oral and once-weekly subcutaneous versions. Both remain investigational. The often-cited 13.1% result came from a small, 12-week Phase 1 oral cohort. Later studies have evaluated both routes, and Phase 3 programs are intended to determine whether either formulation has a benefit-risk profile that supports regulatory approval.
Did zenagamtide cause 13.1% weight loss in 12 weeks?
Novo Nordisk reported a 13.1% mean reduction after 12 weeks in an exploratory oral Phase 1 cohort, compared with 1.1% for placebo. The active group had 16 participants. That is a promising early signal, but it is not proof that every patient would lose that amount, that the effect is faster or stronger than another drug, or that the same result will hold in larger Phase 3 populations.
What is the zenagamtide AMAZE 7 trial?
AMAZE 7 is a Phase 3 randomized trial designed to compare once-weekly subcutaneous zenagamtide with once-weekly subcutaneous semaglutide in an estimated 650 adults with obesity. The ClinicalTrials.gov record was not yet recruiting on June 25, 2026, listed an estimated September 2026 start, and measures relative body-weight change through week 84. It has no efficacy or safety results yet and does not establish that zenagamtide is better than semaglutide.
Do not use an investigational name, trial dose, or online research listing as a substitute for approved care. This page does not recommend treatment, sourcing, or participation in a clinical trial.
Understand the product-category boundary →